645
Participants
Start Date
May 31, 2014
Primary Completion Date
June 30, 2017
Study Completion Date
September 30, 2017
E10030
bevacizumab or aflibercept
Patients are randomized to receive either bevacizumab or aflibercept
E10030 sham injection
Pressure on the eye with a syringe with no needle
Zagreb
Budapest
Budapest
Budapest
Budapest
Budapest
Santa Fe
Sydney
Westmead
Parramatta
Albury
East Melbourne
Debrecen
Stavanger
Córdoba
Szeged
Pécs
Graz
Veszprém
New York
Torino
Tallinn
Tallinn
Marseille
Syracuse
Rochester
West Mifflin
A Coruña
Camp Hill
Philadelphia
Philadelphia
Milan
Milan
Milan
Hamburg
Chevy Chase
Towson
Baltimore
Hagerstown
Richmond
Virginia Beach
Lübeck
Kiel
Morgantown
Winston-Salem
Asheville
West Columbia
Ladson
Marietta
Atlanta
Augusta
Osijek
Pamplona
Tallahassee
Pensacola
Altamonte Springs
Melbourne
Oviedo
Udine
Fort Lauderdale
Palm Beach Gardens
Boynton Beach
Tampa
St. Petersburg
Largo
Winter Haven
Fort Myers
Las Palmas de Gran Canaria
Padua
Tours
Göttingen
Bologna
Paducah
Columbus
Fort Worth
Cleveland
Ferrara
Cleveland
Valencia
Bilbao
Southfield
Münster
Lansing
Jackson
West Des Moines
Rijeka
Aachen
Mainz
Minneapolis
Rapid City
Ancona
Oak Forest
Peoria
Chesterfield
St Louis
St Louis
Tel Aviv
Shawnee Mission
Leawood
Topeka
Strasbourg
Wichita
Omaha
Lyon
Lyon
Kuopio
Tübingen
Oklahoma City
Goiânia
Paris
Paris
Paris
Plano
Dallas
Paris
Willow Park
Rouen
Rehovot
Karlsruhe
San Antonio
San Antonio
McAllen
Amarillo
Abilene
Aurora
Denver
Golden
Colorado Springs
Salt Lake City
Salt Lake City
Phoenix
Gilbert
Tucson
Tucson
Albuquerque
Las Vegas
Reno
Jerusalem
Trenčín
La Jolla
Palm Desert
Redlands
Irvine
Santa Ana
Fullerton
Ventura
Fresno
Créteil
Mountain View
San Francisco
Campbell
Sacramento
Sacramento
Portland
Portland
Bellevue
Silverdale
Bogotá
Haifa
Kfar Saba
Pita Tikva
Hamden
New London
Boston
Boston
Peabody
Worcester
Lawrenceville
Buenos Aires
Buenos Aires
Buenos Aires
Buenos Aires
São Paulo
São Paulo
Vancouver
Vancouver
Winnipeg
Mississauga
Montral
Medellín
Brno
Hradec Králové
Olomouc
Prague
Prague
Helsinki
Leipzig
Roma
Roma
Riga
Riga
Bydgoszcz
Katowice
Lodz
Wroclaw
Coimbra
Coimbra
Lisbon
Lisbon
Porto
Vila Franca de Xira
Banská Bystrica
Albacete
Barcelona
Barcelona
Barcelona
Barcelona
Lead Sponsor
Ophthotech Corporation
INDUSTRY